| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Department of Pharmacology and the Cancer Research Center, College of Physicians and Surgeons of Columbia University, New York, New York 10032
The mouse skin tumor promoter phorbol-12, 13-dibutyrate (PDBU) reversibly enhanced neurite outgrowth in SH-SY5Y human neuroblastoma cells, whether serum was present or absent. The half-maximum response in serum occurred at 10 nM. The binding of [20-3H]phorbol-12, 13-dibutyrate ([3H]PDBU) was studied. Five mouse skin tumor promoters, which included teleocidin, mezerein, and three structural congeners of phorbol, enhanced neurite outgrowth and inhibited binding of [3H]PDBU, but two nonpromoting phorbol congeners did neither. Saccharin and cyclamate, promoters in rat bladder, did not inhibit [3H]PDBU binding. Binding of 10 nM [3H]PDBU at 37° was maximal within 5 min and stable for at least 5 hr. Down modulation of binding was not detected. Following binding at 37°, the dissociation rate in excess PDBU was biphasic, whether measured at 37° or at 4°. The Scatchard curve was also consistent with two types of sites, about 2.5 x 105 sites/cell with Kd = 8.6 nM and 1.2 x 106 sites with Kd = 125 nM. Negative cooperativity was not observed. In short-term assays, nerve growth factor (NGF) did not alter [3H]PDBU binding, and phorbol ester promoters did not alter 125I-NGF binding. Furthermore, [3H]PDBU binding was unaltered following growth of cells for 1 week in PDBU or NGF, conditions under which neurite outgrowth was continuously enhanced, and other phenotypic expressions of differentiation are known to be increased. Specific [3H]PDBU binding sites were present in five neuroblastoma cell lines, two of which are responsive and three unresponsive by neurite outgrowth to promoters and NGF, suggesting the possibility of a common lesion in distal steps in the unresponsive lines.
1 Supported in part by Grant R01 NS 14218 from the National Institute of Neurological Communicative Diseases and Stroke.
2 Predoctoral fellow, recipient of support in part from the Dr. and Mrs. S. C. Wang Fund and from USPHS Training Grant GM 07182 from the Division of General Medical Sciences.
3 Recipient of USPHS Research Career Development Award 1K04 NS00375. To whom requests for reprints should be addressed.
Received 3/ 9/83. Accepted 6/ 6/83.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |